Navigation Links
ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
Date:9/10/2009

IRVINE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the NewsMakers in the Biotech Industry Conference at 11:30 a.m. Eastern Time on September 16, 2009, at the Millennium Broadway Hotel in New York, NY.

ISTA's Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail will provide an update on the Company's commercial and clinical progress. To access the live audio broadcast, or the subsequent archived recording, log ontohttp://www.istavision.com. Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website athttp://www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... BellBrook Labs is formalizing a significant expansion ... biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services will ... inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on drug ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC ... GGI's mission is to advance global health and highlight the greater good of clinical ... each clinical trial volunteer. The vision of GGI is to serve as a philanthropic ...
(Date:2/22/2017)... 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet ... innovative biopharmaceutical products for companion animals, will host a live ... ET to discuss financial results from the fourth quarter and ... participants and investors may access the audio webcast ... ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):